Patents by Inventor Karim Lalji

Karim Lalji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION
    Publication number: 20140343069
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Applicant: Sunovion Inc.
    Inventors: Karim LALJI, Timothy BARBERICH, Judy CARON, Thomas WESSEL
  • Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20140315910
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 23, 2014
    Inventors: Judy Caron, Thomas Wessel, Karim LALJI, Mark Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Han, Stefan G. Koenig
  • Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine
    Patent number: 8329950
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: December 11, 2012
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Han, Stefan G. Koenig
  • Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20120123164
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 17, 2012
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Judy CARON, Thomas Wessel, Karim Lalji, Mark A. Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Steve Han, Stefan G. Koenig
  • COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION
    Publication number: 20120122874
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 17, 2012
    Applicant: Sunovion Inc.
    Inventors: Karim LALJI, Timothy J. BARBERICH, Judy CARON, Thomas WESSEL
  • Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
    Patent number: 8097625
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: January 17, 2012
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Karim Lalji, Timothy J. Barberich, Judy Caron, Thomas Wessel
  • Combinations of Eszopiclone and an Antidepressant
    Publication number: 20090111817
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: July 5, 2006
    Publication date: April 30, 2009
    Applicant: SEPRACOR INC.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney
  • Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20090111818
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: July 5, 2006
    Publication date: April 30, 2009
    Applicant: SEPRACOR INC.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney
  • Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
    Publication number: 20080293726
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: July 6, 2006
    Publication date: November 27, 2008
    Applicant: SEPRACOR INC.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Steve Han, Stefan G. Koenig
  • COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION
    Publication number: 20070299055
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Application
    Filed: June 11, 2007
    Publication date: December 27, 2007
    Applicant: SEPRACOR INC.
    Inventors: Karim Lalji, Timothy Barberich, Judy Caron, Thomas Wessel
  • Modafinil combination therapy for improving sleep quality
    Publication number: 20050215521
    Abstract: One aspect of the present invention relates to pharmaceutical compositions comprising a compound that modulates the orexin system and a sedative agent. In a preferred embodiment, the compound that modulates the orexin system is modafinil and the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in the treatment of various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from a sleep abnormality or insomnia comprising administering a therapeutically effective amount of a pharmaceutical composition of the invention.
    Type: Application
    Filed: December 21, 2004
    Publication date: September 29, 2005
    Inventors: Karim Lalji, Timothy Barberich
  • Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
    Publication number: 20050176680
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.
    Type: Application
    Filed: December 8, 2004
    Publication date: August 11, 2005
    Applicant: Sepracor, Inc.
    Inventors: Karim Lalji, Timothy Barberich, Judy Caron, Thomas Wessel